Article Text

Download PDFPDF

222-I A single-domain antibody-based PET tracer to visualize human CD4-positive cells in vivo
  1. Bjoern Traenkle
  1. NMI, Reutlingen, BWue, Germany
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background CD4+ T cells play essential roles in the development and regulation of autoimmune diseases and cancer. Recently, we have developed single-domain antibodies that bind with high affinity to human CD4 receptor without affecting T cell function. The lead candidate was radiolabeled with NODAGA and Cu-64 (64Cu-αCD4-sdAb) for PET imaging. The aim of this study was to evaluate the applicability of our 64Cu-αCD4-sdAb to visualize and differentiate minimal changes in the CD4+ immune infiltrate during cancer immunotherapy and in inflamed tissue.

Methods 64Cu-αCD4-sdAb was administered intravenously in two orthotopic cancer models and a cutaneous Delayed-Type-Hypersensitivity-Reaction (cDTHR) model. In the first approach, PyMT breast cancer and B16 melanoma cells were implanted in C57BL/6J human-CD4 knock-in (hCD4KI) or wildtype (WT) mice. A subgroup of animals was additionally treated with therapeutic αPD1/α41BB antibodies. To induce cDTHR, hCD4KI mice were sensitized at the abdomen and repetitively challenged at one ear with trinitrochlorobenzene (TNCB). 64Cu-αCD4-sdAb PET/MRI was conducted 24 h after the 5th TNCB-ear challenge and organs of interest were harvested for ex vivo biodistribution, immunohistochemistry or mass cytometry (CyTOF) analyses immediately after the last imaging time-point.

Results Dynamic 64Cu-αCD4-sdAb PET/MRI of PyMT tumors over 6 h revealed the best differentiation between hCD4KI and WT mice at 1.5 h and 3 h imaging time-point post tracer injection. In line with ex vivo analyses of intratumoral CD4+ cell densities, αPD1/α41BB-treated PyMT tumors of hCD4KI mice showed significantly higher 64Cu-αCD4-sdAb uptake (0.46±0.01%ID/ml) compared to untreated littermates (0.30±0.03%ID/ml) and PyMT tumors of WT mice (0.21±0.02%ID/ml). In contrast, B16 tumors with histologically almost absent CD4+ cell infiltrates yielded an uptake of 0.23±0.02%ID/ml similar to WT mice. In the cDTHR model, the 64Cu-αCD4-sdAb uptake in the inflamed ears was 3-fold higher compared to control ears. Importantly, a control sdAb tracer did not reveal such differences in the inflamed and non-inflamed ears, excluding relevant non-specific perfusion effects. Immunohistochemistry revealed a rare number of CD4+ cells in the inflamed tissues being detectable by out extremely sensitive PET/MRI approach.

Conclusions Due to the important role of CD4+ cells in health and disease, precise non-invasive imaging approaches to visualize and monitor CD4+ cells in vivo are urgently needed. Our newly developed 64Cu-αCD4-sdAb PET tracer is able to detect small amounts of CD4+-cell infiltrates in both cancer and cDTHR models, pointing out its potential to serve as a versatile probe for a broad range of T cell-associated diseases.

Ethics Approval All animal experiments were carried out in accordance with the German Animal Welfare Act and with consent of regulatory authorities (Regierungspräsidium Tübingen).

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.